Automated Solutions for Cellular Screening and Characterization of Therapeutic Antibodies for Antibody-Dependent Cellular Cytotoxicity Utility
Poster Feb 16, 2012
Brad Larson, Peter Banks , Nicolas Pierre, Stéphane Martinez, and Francois Degorce
Since the end of the 1990’s, the pharmaceutical industry has seen an increased interest in biologics, especially in the therapeutic areas of oncology and inflammation. The selection of potent and selective Mabs (monoclonal antibodies) for specific target receptors, such as Receptor Tyrosine Kinase (RTK) and G protein-coupled receptors (GPCRs), is the first step in successfully developing an antibody based drug. In addition to potent binding, some antibodies have the ability to recruit the immune system effector cells, a process known as ADCC (Antibody Dependent Cell Cytotoxicity). The ability to promote ADCC is an important attribute of successful candidates and for that reason should be sought in the final drug design.
Performance of the D5000 and High Sensitivity D5000 ScreenTape Assays for the 4200 TapeStation SystemPoster
Here, we focus on quantification, sizing, and sensitivity of both D5000 ScreenTape assays.READ MORE
CiPA Phase 2 Study: validation of an automated microelectrode array (MEA) assay of hiPSC-derived cardiomyocyte electrophysiology for cardiac safety evaluationPoster
These results support the use of hSC-CM and MEA technology for preclinical assessment of proarrhythmic risk within the proposed CiPA paradigm, and, more generally, demonstrate that automation of the CM-MEA assay can achieve high reliability and throughput for cardiac risk assessment in vitro.READ MORE